Material Event (Form 8-K)

Item 8.01. Other Events

As previously reported, on May 6, 2025, NeuroOne Medical Technologies Corporation (the "Company") received a deficiency letter (the "Bid Price Notice") from the Listing Qualifications Department (the "Staff") of the Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that because the closing bid price per share of the Company's common stock was below $1.00 per share for 30 consecutive business days preceding the date of the Bid Price Notice, the Company did not meet the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Rule").

On April 30, 2026, the Company received a letter from the Staff notifying the Company that it had regained compliance with the Bid Price Rule as a result of the closing bid price of the Company's common stock being at $1.00 per share or greater for the prior 10 consecutive business days. Accordingly, the letter indicated the Company is in compliance with the Bid Price Rule and the matter is closed.